Salisbury Margaret L, Wijsenbeek Marlies S
Department of Medicine, Division of Allergy, Pulmonary and Critical Care, Vanderbilt University Medical Center, 1161 21st Avenue South, T-1209A Medical Center North, Nashville, TN 37232, USA.
Department of Respiratory Medicine, Centre for Interstitial Lung Diseases and Sarcoidosis, Erasmus Medical Center, University Medical Centre Rotterdam, Dr. Molewaterplein 40, Rotterdam 3015, GD, the Netherlands.
Clin Chest Med. 2021 Jun;42(2):275-285. doi: 10.1016/j.ccm.2021.03.004.
Progress in the past 2 decades has led to widespread use of 2 medications to slow loss of lung function in patients with pulmonary fibrosis. Treatment of individual patients with currently available pharmacotherapies can be limited by side effects, and neither drug has a consistent effect on patient symptoms or function. Several promising new pharmacotherapies are under development. Comprehensive management of pulmonary fibrosis hinges on shared decision making. Patient and caregiver education, and early identification and management of symptoms and comorbidities, can help improve quality of life.
过去20年的进展使得两种药物得以广泛应用于减缓肺纤维化患者肺功能的丧失。使用目前可用的药物疗法治疗个体患者可能会受到副作用的限制，而且这两种药物对患者症状或功能都没有一致的效果。几种有前景的新药物疗法正在研发中。肺纤维化的综合管理取决于共同决策。对患者和护理人员的教育，以及症状和合并症的早期识别与管理，有助于提高生活质量。
